DOCSLIB.ORG

MDMA (Ecstasy) Inhibition of MAO Type a and Type B: Comparisons with Fenfluramine and Fluoxetine (Prozac) Efthimia T

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
MDMA (Ecstasy) Inhibition of MAO Type a and Type B: Comparisons with Fenfluramine and Fluoxetine (Prozac) Efthimia T NEUROPSYCHOPHARMACOLOGY 1994-VOL. 10, NO.4 231 MDMA (Ecstasy) Inhibition of MAO Type A and Type B: Comparisons with Fenfluramine and Fluoxetine (Prozac) Efthimia T. Kokotos Leonardi, M.S. and Efrain C. Azmitia, Ph.D. 3,4-Methylenedioxymethamphetamine (MDMA), a fenfiuramine (FEN) and fiuoxetine (FLUOX) were serotonin (5-HT) neurotoxin, has been shown to promote compared to those of MDMA. The rank order potency of the release of serotonin (5-HT) and block its reuptake. these drugs for MAO-A inhibition was The increased buildup of extracellular 5-HT should MDMA>FLUOX>FEN, whereas for MAO-B inhibition, normally be degraded by monoamine oxidase (MAO). The FLUOX>MDMA>FEN. A combination of FLUOX and effects of both enantiomers of MDMA were examined on MDMA at their respective lC50 did not inhibit MAO MAO-A and monoamine oxidase-B (MAO-B) activity in activity more than either drug alone at equivalent rat brain homogenates. Both enantiomers competitively concentrations. These results indicate that the actions of inhibited 5-HT catabolism by rat brain MAO-A. The Ki FEN do not appear to involve MAO inhibition. MDMA of MDMA for MAO-A was 22 J.lmollL. A mixed type of (ecstasy) produced a preferential inhibition of MAO-A inhibition by MDMA was observed for phenethylamine (1C50 = 44 J.lmoIlL), which should increase extracellular catabolism by MAO-B for both optical antipodes. 5-HT. This may explain its high toxicity potential. Logistical analysis of concentration response curves for Finally, FLUOX (Prozac) showed an inhibition of MDMA inhibition of MAO-A and MAO-B show an lC50 MAO-B (1C50 = 80 J.lmoIlL, which may increase the of 44 J.lmollL for inhibition of MAO-A by MDMA. The intracellular content of 5-HT. This may contribute to its lC50 value of MDMA inhibition of MAO-B was 370 therapeutic potential. In contrast, FEN appears to be a J.lmollL, showing a selective potency for MAO-A poor inhibitor of both MAO-A and MAO-B. inhibition. The MAO inhibitory properties of [Neuropsychopharmacology 10:231-238, 1994] KEY WORDS: Serotonin; Phenethylamine; Enantiomer for serotonin is 1170 IlmollL (Fowler and Tipton 1982; Garrick and Murphy 1982). Monoamine oxidase A is Monoamine oxidase (MAO) is an enzyme with two sub­ inhibited by nanomolar concentrations of clorgyline types (E. C.1.4.3.4) characterized by their differentialre­ (Johnston 1968). Monoamine oxidase B (MAO-B) has sponses to the irreversible inhibitors clorgyline and a higher affinityfor phenethylamine than MAO-A and depreny1. Monoamine oxidase A (MAO-A) has a higher is inhibited by nanomolar concentrations of deprenyl affinity for serotonin (5-HT) than MAO-B; the KM of (Garrick and Murphy 1982; Yang and Neff1974). Dopa­ MAO-A for serotonin is 99 IlmollL, the KM of MAO-B mine (DA) is metabolized with equal affinity by both subtypes (Yang and Neff 1974). Further evidence for two molecular forms of MAO has been provided by the From the Department of Biology, New York University, New York, New York. cloning of two distinct MAO genes (Bach et a1. 1988) Address correspondence to Dr. Efrain C. Azmitia, Department of and their subsequent functional expression inCOS cells Biology, New York University, 100 Washington Square East, New (Lan et a1. 1989). York, NY 10003. Received November 7, 1993; revised February 16, 1994; accepted Both neurons and glia contain monoamine oxidases February 17, 1994. that catabolize the classical monoamine neurotransmit- © 1994 American College of Neuropsychopharmacology Published by Elsevier Science Inc. 655 Avenue of the Americas, New York, NY 10010 0893-133X/94/$7.00 232 E.T. Kokotos Leonardi and E.C. Azmitia NEUROPSYCHOPHARMACOLOGY 1994-VOL.10, NO. 4 ters. Monoamine oxidase A is the predominant form to the transporter for these agents is FLUOX>FEN = in catecholaminergic neurons, whereas MAO-B is the MDMA (Poblete et al. 1989). prevalent form in glia (Levitt et al. 1982; Westlund et The similar actions of FEN, FLUOX and MDMA on al. 1985). Although MAO-B has a higher affinity than serotonin transporter binding suggest they may pos­ MAO-B for serotonin, MAO-B is the major molecular sess common effects upon other serotonergic param­ form found within serotonergic neurons (Westlund et eters, such as monoamine oxidase activity, in vitro. The al. 1985). present report examines the effectsof both enantiomers 3,4-Methylenedioxymethamphetamine (MDMA) of MDMA on catabolism of [3H]-serotonin and p4C]­ binds with high affInity to the 5-HT transporter pro­ phenethylamine by rat brain monoamine oxidase in tein (Poblete et al. 1989) and has been shown to be a vitro. In addition, we compared the effects of fluoxe­ potent releaser of serotonin by a Ca2+-independent tine (FLUOX) and fenfluramine (FEN) to MDMA on rat mechanism (Berger et al. 1992; Gu and Azmitia 1989; brain MAO activity. Our results suggest that inhibition Johnson et al. 1986; Schmidt 1987; Schmidt et al. 1987). of MAO-A by MDMA may contribute to an accumula­ MDMA has been demonstrated to produce a depletion tion of extracellular 5-HT. The inhibition of MAO-B ac­ of serotonin that may be reversed in acute stages by tivity by FLUOX may increase intracellular 5-HT, agents that bind to the serotonin transporter and block whereas the actions of FEN do not appear to involve serotonin reuptake into presynaptic terminals (Azmitia MAO inhibition. et al. 1990; Schmidt 1987). It also inhibits the 5-HT re­ uptake system (Steele et al. 1987), resulting in an in­ creased amount of extracellular 5-HT. However, little MATERIALS AND METHODS attention has been paid to the fate of extracellular 5-HT. Parachloroamphetamine (PCA) is another sub­ Male Sprague-Dawley rats weighing 200 to 250 g (Ta­ stituted amphetamine that is a potent releaser of sero­ conic Farms, Germantown, NY) were housed two per tonin and has a biphasic depletion of serotonin similar cage and given free access to food and water. The to that observed with MDMA (Ask and Ross 1987; animals were maintained on a 12-hour light/dark cy­ Berger et al. 1992; Fuller et al. 1975; Gu and Azmitia cle. Animals were euthanized with C02 and decapi­ 1989; Gu 1993; Hwang and van Woert 1980; Mamounas tated according to a protocol approved by the NYU An­ and Molliver 1988; Poblete et al. 1989; Ross and Froden imal Welfare Committee. Brains were rapidly removed 1977). As with MDMA, the depletion of serotonin resul­ and placed on ice in 0.32 mollL sucrose. After removal tant from PCA may be reversed in its acute phase by of the cerebellum, brains were homogenized in 10-fold serotonin uptake blockers (Fuller et al. 1975; Ross et al. volume/weight in 0.32 mollL sucrose using 10 strokes 1977). Parachloroamphetamine has been shown to in­ with a Teflon/glass homogenizer. P1 pellets were pre­ hibit MAO-A activity in rat brain homogenates with a pared by sedimentation of homogenates at 800 x g for Ki value of 1.31 IlmollL (Fuller 1966). The toxicity of 10 minutes at 2°C in a Sorvall RC5C centrifuge (Sorvall PCA is also affected by the amount of releasable sero­ Instruments, DuPont, Chadds Ford, PA). Supernatants tonin into the extracellular space. For instance, ifsero­ were resedimented at 14,000 xg at 2°C for 15 minutes tonin release is decreased by parachlorophenylalanine to obtain a crude mitochondrial P2 pellet. Resultant (pCP A) and reserpine, the level of toxicity is reduced pellets were resuspended in 500 ilL 0.32 mollL sucrose (Berger et al. 1989). and stored at -70°C until use. The anorectic compound, fenfluramine (FEN), is Prior to the MAO assay, homogenates were thawed a halogenated amphetamine that has actions in and brought up to lOx volume/original weight 0.01 serotonergic axon terminals similar to those of MDMA mollL sodium phosphate buffer (PB), pH 7.4 and and PCA (Mamounas and Molliver 1988; Molliver and dialyzed to remove endogenous monoamines by a Molliver 1990; O'Hearn et al. 1988). Like MDMA and modiflcationof the method described by Patterson, et PCA, FEN causes the release of 5-HT from presynaptic al. (1973). Briefly, homogenates were dialyzed in 2 mL terminals (Borroni et al. 1983) and inhibits the reuptake aliquots using 3500 mw cutoff dialysis tubing (Spec­ of serotonin into its terminals (Belin et al. 1976; Kan­ trap or) against 0.01 mollL PB, pH 7.4 at 4°C for 2 hours nengiesser et al. 1976). The effects of FEN are blocked with three successive changes of 1L buffer. MAO as­ by 5-HT uptake inhibitors, as in MDMA and PCA (Hek­ says were performed immediately following this di­ matpanah and Peroutka 1990). These observations sug­ alysis. gest that the carrier-mediated release of serotonin and Monamine oxidase activity was assayed using the inhibition of its reuptake are critical components [3H]-5-HT (25Ci/mmol, 1IlCi/mL, New England Nu­ in the mechanism of these drugs. FEN, FLUOX, and clear, Boston, MA) as a substrate for MAO-A at fmal MDMA bind to the serotonin transporter protein with concentrations ranging from 12.5IlmollL to 400IlmollL. high affinity; the rank order potencies for binding p4C]-phenethylamine at a fmal concentration of 5 NEUROPSYCHOPHARMACOLOGY 1994-VOL. 10, NO. 4 MDMA Inhibition of MAO-A 233 15000 tillation counting in Beckman lS 1801 scintillation 14000 ... counter (Fullerton, CA) with a counting efficiency 13000 • � 0 uM !.IOMA � o '" 5 uU UOUA " 12000 " = 10 uU UOMA of 40%. c " - 50 uU I.IDUA 11000 E • = 100 uU UO!.l I 10000 � D = 500 u!.l UD e Comparison of FEN, FLUOX, and MDMA � ... 9000 A = 1 m!.l !.IDMA � '" 8000 < E Fenfluramine, FLUOX, and each enantiomer of MDMA I .....
Load more

Recommended publications
  • Neurotransmitter Resource Guide
    NEUROTRANSMITTER RESOURCE GUIDE Science + Insight doctorsdata.com Doctor’s Data, Inc. Neurotransmitter RESOURCE GUIDE Table of Contents Sample Report Sample Report ........................................................................................................................................................................... 1 Analyte Considerations Phenylethylamine (B-phenylethylamine or PEA) ................................................................................................. 1 Tyrosine .......................................................................................................................................................................................... 3 Tyramine ........................................................................................................................................................................................4 Dopamine .....................................................................................................................................................................................6 3, 4-Dihydroxyphenylacetic Acid (DOPAC) ............................................................................................................... 7 3-Methoxytyramine (3-MT) ............................................................................................................................................... 9 Norepinephrine ........................................................................................................................................................................
    [Show full text]
  • Methylphenidate Hydrochloride
    Application for Inclusion to the 22nd Expert Committee on the Selection and Use of Essential Medicines: METHYLPHENIDATE HYDROCHLORIDE December 7, 2018 Submitted by: Patricia Moscibrodzki, M.P.H., and Craig L. Katz, M.D. The Icahn School of Medicine at Mount Sinai Graduate Program in Public Health New York NY, United States Contact: [email protected] TABLE OF CONTENTS Page 3 Summary Statement Page 4 Focal Point Person in WHO Page 5 Name of Organizations Consulted Page 6 International Nonproprietary Name Page 7 Formulations Proposed for Inclusion Page 8 International Availability Page 10 Listing Requested Page 11 Public Health Relevance Page 13 Treatment Details Page 19 Comparative Effectiveness Page 29 Comparative Safety Page 41 Comparative Cost and Cost-Effectiveness Page 45 Regulatory Status Page 48 Pharmacoepial Standards Page 49 Text for the WHO Model Formulary Page 52 References Page 61 Appendix – Letters of Support 2 1. Summary Statement of the Proposal for Inclusion of Methylphenidate Methylphenidate (MPH), a central nervous system (CNS) stimulant, of the phenethylamine class, is proposed for inclusion in the WHO Model List of Essential Medications (EML) & the Model List of Essential Medications for Children (EMLc) for treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) under ICD-11, 6C9Z mental, behavioral or neurodevelopmental disorder, disruptive behavior or dissocial disorders. To date, the list of essential medications does not include stimulants, which play a critical role in the treatment of psychotic disorders. Methylphenidate is proposed for inclusion on the complimentary list for both children and adults. This application provides a systematic review of the use, efficacy, safety, availability, and cost-effectiveness of methylphenidate compared with other stimulant (first-line) and non-stimulant (second-line) medications.
    [Show full text]
  • Investigating Interactions Between Phentermine, Dexfenfluramine, and 5-HT2C Agonists, on Food Intake in the Rat
    Psychopharmacology DOI 10.1007/s00213-014-3829-2 ORIGINAL INVESTIGATION Investigating interactions between phentermine, dexfenfluramine, and 5-HT2C agonists, on food intake in the rat Andrew J. Grottick & Kevin Whelan & Erin K. Sanabria & Dominic P. Behan & Michael Morgan & Carleton Sage Received: 2 October 2014 /Accepted: 20 November 2014 # The Author(s) 2014. This article is published with open access at Springerlink.com Abstract Conclusions Dex-phen synergy in the rat is caused by a Rationale Synergistic or supra-additive interactions between pharmacokinetic interaction, resulting in increased central the anorectics (dex)fenfluramine and phentermine have been concentrations of phentermine. reported previously in the rat and in the clinic. Studies with 5- HT2C antagonists and 5-HT2C knockouts have demonstrated Keywords Synergy . BELVIQ® . Lorcaserin . Isobologram . dexfenfluramine hypophagia in the rodent to be mediated by Fen-phen actions at the 5-HT2C receptor. Given the recent FDA approv- al of the selective 5-HT2C agonist lorcaserin (BELVIQ®) for weight management, we investigated the interaction between Introduction phentermine and 5-HT2C agonists on food intake. Objectives This study aims to confirm dexfenfluramine- Fenfluramine (Pondimin) and dexfenfluramine (Redux) are phentermine (dex-phen) synergy in a rat food intake assay, anorectic agents which act to enhance serotonergic transmission to extend these findings to other 5-HT2C agonists, and to both through inhibition of 5-HT reuptake by the parent com- determine whether pharmacokinetic interactions could ex- pounds, and through their major circulating des-ethylated me- plain synergistic findings with particular drug combinations. tabolite, (dex)norfenfluramine, which is a 5-HT reuptake inhib- Methods Isobolographic analyses were performed in which itor, a 5-HT and noradrenaline releasing agent, and a potent phentermine was paired with either dexfenfluramine, the 5- agonist at postsynaptic 5-HT2 receptors (Curzon et al.
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
    [Show full text]
  • Comparison of the Characteristic Mass Fragmentations of Phenethylamines and Tryptamines by Electron Ionization Gas Chromatograph
    applied sciences Article Comparison of the Characteristic Mass Fragmentations of Phenethylamines and Tryptamines by Electron Ionization Gas Chromatography Mass Spectrometry, Electrospray and Matrix-Assisted Laser Desorption Ionization Mass Spectrometry Bo-Hong Chen, Ju-Tsung Liu, Hung-Ming Chen, Wen-Xiong Chen and Cheng-Huang Lin * Department of Chemistry, National Taiwan Normal University, 88 Sec. 4 Tingchow Road, Taipei 11677, Taiwan; [email protected] (B.-H.C.); [email protected] (J.-T.L.); [email protected] (H.-M.C.); [email protected] (W.-X.C.) * Correspondence: [email protected]; Tel.: +886-2-7734-6170; Fax: +886-2-2932-4249 Received: 18 April 2018; Accepted: 19 June 2018; Published: 22 June 2018 Abstract: Characteristic mass fragmentation of 20 phenethylamine/tryptamine standards were investigated and compared by means of matrix assisted laser desorption/time-of-flight mass spectrometry (MALDI/TOFM), gas chromatography–electron ionization–mass spectrometry (GC-EI/MS) and liquid chromatography–electrospray ionization/mass spectrometry (LC-ESI/MS) + methods. As a result, three characteristic peaks ([M] and fragments from the Cβ-Cα bond breakage) were found to be unique and contained information useful in identifying 2C series compounds based on the GC-EI/MS method. We found that the protonated molecular ion ([M+H]+) and two types of fragments produced from the α-cleavage and β-cleavage processes were useful mass spectral information in the rapid screening and confirmation of phenethylamine and tryptamine derivatives when ESI/MS and MALDI/TOFMS methods were applied. This assay was successfully used to determine samples that contain illicit drugs. Keywords: phenethylamine; tryptamine; MALDI/TOFMS; GC-EI/MS; LC-ESI/MS 1.
    [Show full text]
  • Selective Labeling of Serotonin Receptors Byd-[3H]Lysergic Acid
    Proc. Nati. Acad. Sci. USA Vol. 75, No. 12, pp. 5783-5787, December 1978 Biochemistry Selective labeling of serotonin receptors by d-[3H]lysergic acid diethylamide in calf caudate (ergots/hallucinogens/tryptamines/norepinephrine/dopamine) PATRICIA M. WHITAKER AND PHILIP SEEMAN* Department of Pharmacology, University of Toronto, Toronto, Canada M5S 1A8 Communicated by Philip Siekevltz, August 18,1978 ABSTRACT Since it was known that d-lysergic acid di- The objective in this present study was to improve the se- ethylamide (LSD) affected catecholaminergic as well as sero- lectivity of [3H]LSD for serotonin receptors, concomitantly toninergic neurons, the objective in this study was to enhance using other drugs to block a-adrenergic and dopamine receptors the selectivity of [3HJISD binding to serotonin receptors in vitro by using crude homogenates of calf caudate. In the presence of (cf. refs. 36-38). We then compared the potencies of various a combination of 50 nM each of phentolamine (adde to pre- drugs on this selective [3H]LSD binding and compared these clude the binding of [3HJLSD to a-adrenoceptors), apmo ie, data to those for the high-affinity binding of [3H]serotonin and spiperone (added to preclude the binding of [3H[LSD to (39). dopamine receptors), it was found by Scatchard analysis that the total number of 3H sites went down to 300 fmol/mg, compared to 1100 fmol/mg in the absence of the catechol- METHODS amine-blocking drugs. The IC50 values (concentrations to inhibit Preparation of Membranes. Calf brains were obtained fresh binding by 50%) for various drugs were tested on the binding of [3HLSD in the presence of 50 nM each of apomorphine (A), from the Canada Packers Hunisett plant (Toronto).
    [Show full text]
  • Pharmacology and Toxicology of Amphetamine and Related Designer Drugs
    Pharmacology and Toxicology of Amphetamine and Related Designer Drugs U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES • Public Health Service • Alcohol Drug Abuse and Mental Health Administration Pharmacology and Toxicology of Amphetamine and Related Designer Drugs Editors: Khursheed Asghar, Ph.D. Division of Preclinical Research National Institute on Drug Abuse Errol De Souza, Ph.D. Addiction Research Center National Institute on Drug Abuse NIDA Research Monograph 94 1989 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Alcohol, Drug Abuse, and Mental Health Administration National Institute on Drug Abuse 5600 Fishers Lane Rockville, MD 20857 For sale by the Superintendent of Documents, U.S. Government Printing Office Washington, DC 20402 Pharmacology and Toxicology of Amphetamine and Related Designer Drugs ACKNOWLEDGMENT This monograph is based upon papers and discussion from a technical review on pharmacology and toxicology of amphetamine and related designer drugs that took place on August 2 through 4, 1988, in Bethesda, MD. The review meeting was sponsored by the Biomedical Branch, Division of Preclinical Research, and the Addiction Research Center, National Institute on Drug Abuse. COPYRIGHT STATUS The National Institute on Drug Abuse has obtained permission from the copyright holders to reproduce certain previously published material as noted in the text. Further reproduction of this copyrighted material is permitted only as part of a reprinting of the entire publication or chapter. For any other use, the copyright holder’s permission is required. All other matieral in this volume except quoted passages from copyrighted sources is in the public domain and may be used or reproduced without permission from the Institute or the authors.
    [Show full text]
  • Mediator°: Norfenfluramine at the Heart of the Trial
    OUTLOOK Mediator°: norfenfluramine at the heart of the trial he verdict in France's Mediator° criminal trial after the human disaster had been revealed. Some is expected at the end of March 2021, twelve drug regulatory agency officials continued to believe T years after this drug, which caused several the company’s claim that the norfenflur amine de- hundreds of people to die from pulmonary arterial rived from benfluorex was only produced in negli- hypertension (PAH) or heart valve disease, was gible quantities, or even that it was not metabolised withdrawn from the French market (1). in the same way as norfenfluramine derived from other fenfluramines (4). The“scientific absurdity” Benfluorex, a fenfluramine just like the of this claim was highlighted by one of the prose- others. One of the key questions in the trial was cutors (b). to establish when the company, Servier, first knew These facts alone are sufficient to explain why that benfluorex could cause PAH (a). the company and the drug regulatory agency have Benfluorex(Mediator° and other brands), fenflur- been criticised for not withdrawing benfluorex from amine (Ponderal° and other brands) and dexfenflur- the market in the mid-1990s at the very latest (6). amine (Isomeride° and other brands) are fenflur- ©Prescrire amines developed by Servier from the 1960s ▶ Translated from Rev Prescrire January 2021 onwards, and inspired by norfenfluramine, a fluorin- Volume 41 N° 447 • Page 59 ated amphetamine derivative with mainly appetite- suppressing properties (2,3). PAH due to appetite-suppressing amphetamines (other than fenfluramines) had been reported since the late 1960s (1,2).
    [Show full text]
  • Amphetamine Derivatives Interact with Both Plasma Membrane and Secretory Vesicle Biogenic Amine Transporters
    '4 0026-895X/93/061227-05503.00/0 Copyright © by The American Society for Pharmacology and Experimental Therapeutics AIl rights of reproduction in any form reserved. MOLECULAR PHARMACOLOGY, 44:1227-1231 Amphetamine Derivatives Interact with Both Plasma Membrane and Secretory Vesicle Biogenic Amine Transporters SHIMON SCHULDINER, SONIA STEINER-MORDOCH, RODRIGO YELIN, STEPHEN C. WALL, and GARY RUDNICK Departmentof Pharmacology,YaleUniversitySchool of Medicine,New Haven,CT 06510 (S.C.W.,G.R.) andAlexanderSilbermanInstituteof Life Sciences,TheHebrew University,GivatRam, Jerusalem,Israel (S.S.,S.S.-M., R.Y.) ReceivedJune 7, 1993; Accepted September 16, 1993 SUMMARY The interaction of fenfluramine, 3,4-methylenedioxymethamphe- porter, fenfiuramine inhibited serotonin transport and dissipated tamine (MDMA), and p-chloroamphetamine (PCA) with the plate- the transmembrane pH difference (ApH) that drives amine up- let plasma membrane serotonin transporter and the vesicular take. The use of [3H]reserpine-binding measurements to deter- amine transporter were studied using both transport and binding mine drug interaction with the vesicular amine transporter al- measurements. Fenfluramine is apparently a substrate for the lowed assessment of the relative ability of MDMA, PCA, and plasma membrane transporter, and consequently inhibits both fenfluramine to bind to the substrate site of the vesicular trans- serotonin transport and imipramine binding. Moreover, fenflura- porter. These measurements permit a distinction between inhi- mine exchanges with internal [3H]serotonin in a plasma mem- bition of vesicular serotonin transport by directly blocking vesic- brane transporter-mediated reaction that requires NaCI and is ular amine transport and by dissipating ApH. The results indicate blocked by imipramine. These properties are similar to those of that MDMA and fenfluramine inhibit by both mechanisms but MDMA and PCA as previously described.
    [Show full text]
  • Understanding Drug-Drug Interactions Due to Mechanism-Based Inhibition in Clinical Practice
    pharmaceutics Review Mechanisms of CYP450 Inhibition: Understanding Drug-Drug Interactions Due to Mechanism-Based Inhibition in Clinical Practice Malavika Deodhar 1, Sweilem B Al Rihani 1 , Meghan J. Arwood 1, Lucy Darakjian 1, Pamela Dow 1 , Jacques Turgeon 1,2 and Veronique Michaud 1,2,* 1 Tabula Rasa HealthCare Precision Pharmacotherapy Research and Development Institute, Orlando, FL 32827, USA; [email protected] (M.D.); [email protected] (S.B.A.R.); [email protected] (M.J.A.); [email protected] (L.D.); [email protected] (P.D.); [email protected] (J.T.) 2 Faculty of Pharmacy, Université de Montréal, Montreal, QC H3C 3J7, Canada * Correspondence: [email protected]; Tel.: +1-856-938-8697 Received: 5 August 2020; Accepted: 31 August 2020; Published: 4 September 2020 Abstract: In an ageing society, polypharmacy has become a major public health and economic issue. Overuse of medications, especially in patients with chronic diseases, carries major health risks. One common consequence of polypharmacy is the increased emergence of adverse drug events, mainly from drug–drug interactions. The majority of currently available drugs are metabolized by CYP450 enzymes. Interactions due to shared CYP450-mediated metabolic pathways for two or more drugs are frequent, especially through reversible or irreversible CYP450 inhibition. The magnitude of these interactions depends on several factors, including varying affinity and concentration of substrates, time delay between the administration of the drugs, and mechanisms of CYP450 inhibition. Various types of CYP450 inhibition (competitive, non-competitive, mechanism-based) have been observed clinically, and interactions of these types require a distinct clinical management strategy. This review focuses on mechanism-based inhibition, which occurs when a substrate forms a reactive intermediate, creating a stable enzyme–intermediate complex that irreversibly reduces enzyme activity.
    [Show full text]
  • N-Alkylation of Phenethylamine and Tryptamine Gerta Cami-Kobeci, Paul A
    Bioorganic & Medicinal Chemistry Letters 15 (2005) 535–537 N-Alkylation of phenethylamine and tryptamine Gerta Cami-Kobeci, Paul A. Slatford, Michael K. Whittlesey and Jonathan M. J. Williams* Department of Chemistry, University of Bath, Claverton Down, Bath BA2 7AY, UK Received 28 October 2004; revised 17 November 2004; accepted 18 November 2004 Available online 24 December 2004 Abstract—A clean and efficient method for the N-alkylation of tryptamine and phenethylamine, employing alcohols as the alkyl- ating agents, has been developed. The reaction proceeds via catalytic electronic activation, involving an iridium catalyst which activates the alcohol by borrowing hydrogen from the substrate, returning it later in the catalytic cycle. Some examples of N-heterocyclisation have been performed employing a diol as the substrate. Ó 2004 Elsevier Ltd. All rights reserved. The ability to prepare a large number of synthetically NMe2 useful and pharmacologically active compounds, either H N OH by traditional or high throughput methods, is becoming Me S O O HN increasingly important. Herein we report an efficient, N atom economic, one-pot method for the N-alkylation H of tryptamine and phenethylamine, giving water as the OH only by-product. Sumatriptan Nylidrin Figure 1. The tryptamine sub-structure is present in numerous naturally occurring and synthetic compounds, many of which exhibit important pharmacological activity. For mercially available iminophosphorane 3.5 The reaction example, a number of 5-alkyltryptamine derivatives proceeds via a strategy
    [Show full text]
  • Differentially Affect Monoamine Transporters and Abuse Liability
    Neuropsychopharmacology (2017) 42, 1950–1961 © 2017 American College of Neuropsychopharmacology. All rights reserved 0893-133X/17 www.neuropsychopharmacology.org N-Alkylated Analogs of 4-Methylamphetamine (4-MA) Differentially Affect Monoamine Transporters and Abuse Liability Ernesto Solis Jr1, John S Partilla2, Farhana Sakloth3, Iwona Ruchala4, Kathryn L Schwienteck5, 4 4 3 5 *,2 Louis J De Felice , Jose M Eltit , Richard A Glennon , S Stevens Negus and Michael H Baumann 1In Vivo Electrophysiology Unit, Behavioral Neuroscience Research Branch, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD, USA; 2Designer Drug Research Unit, Intramural Research Program, National Institute on Drug Abuse, 3 National Institutes of Health, Baltimore, MD, USA; Department of Medicinal Chemistry, Virginia Commonwealth University, Richmond, VA, USA; 4 5 Department of Physiology and Biophysics, Virginia Commonwealth University, Richmond, VA, USA; Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA, USA Clandestine chemists synthesize novel stimulant drugs by exploiting structural templates known to target monoamine transporters for dopamine, norepinephrine, and serotonin (DAT, NET, and SERT, respectively). 4-Methylamphetamine (4-MA) is an emerging drug of – abuse that interacts with transporters, but limited structure activity data are available for its analogs. Here we employed uptake and release assays in rat brain synaptosomes, voltage-clamp current measurements in cells expressing transporters, and calcium flux assays in cells coexpressing transporters and calcium channels to study the effects of increasing N-alkyl chain length of 4-MA on interactions at DAT, NET, and SERT. In addition, we performed intracranial self-stimulation in rats to understand how the chemical modifications affect abuse liability.
    [Show full text]